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In 1992, the Brugada syndrome (BrS) was recognized as a disease responsible for sudden cardiac death,
characterized by a right bundle-branch block with ST segment elevation in the leads V1 and V2. This
syndrome is highly associated with sudden cardiac death, especially in young males. BrS is currently
diagnosed in patients with ST-segment elevation showing type 1 morphology Z 2 mm in Z1 leads
among the right precordial leads V1 or V2 positioned in the 2nd, 3rd, or 4th intercostal space, and
occurring either spontaneously or after a provocative drug test by the intravenous administration of Class
I antiarrhythmic drugs. With accumulated ﬁndings, the BrS inheritance model is believed to be an
autosomal dominant inheritable model with incomplete penetrance, although most patients with BrS
were sporadic cases. SCN5A, which was identiﬁed as the ﬁrst BrS-associated gene in 1998, has emerged as
the most common gene associated with BrS, and more than 10 BrS-associated genes have been identiﬁed
thereafter. Mutation-speciﬁc genetic testing is recommended for the family members and appropriate
relatives following the identiﬁcation of BrS-causative mutations in an index patient. In addition, com-
prehensive or BrS1 (SCN5A) targeted genetic testing could be useful for patients in whom a cardiologist
has established a clinical index of suspicion for BrS based on the patient's clinical history, family history,
and the expressed electrocardiographic (resting 12-lead ECGs and/or provocative drug challenge testing)
phenotype.
Over the past 20 years, extensive research in this ﬁeld has allowed better understanding of the
pathophysiology, genetic background, and management of BrS even though controversies still exist. In
this review article, a background of genetics, the genetic background of BrS, the genotype and phenotype
relationship, the role of genetic screening in clinical practice, and the interpretation of the identiﬁed
genetic variants have been addressed based on this understanding.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
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The human genome contains approximately 3 billion nucleo-
tide base pairs contained in 23 chromosome pairs. Each chromo-
some contains hundreds to thousands of genes and the estimated
30,000 genes in the human genome express approximately
100,000 proteins [1]. The Human Genome Project (HGP) was
proposed in the 1980s and was completed in 2003. The 1000
Genomes Project was conducted between 2008 and 2015, gen-
erating the largest public catalogue of human variations and
genotype data. The completion of these projects provides a source
book for biology, medicine, and genetic research.
Sanger sequencing was used for the genetic screening of BrS
and was considered the gold standard for DNA sequencing in the
subsequent two and a half decades [2]. In the past few years, new
technologies (large-insert clone arrays, oligonucleotide arrays,
target-gene sequencing, whole-exome sequencing (WES), and
whole-genome sequencing (WGS)) have been developed, thus
allowing the detection of medium- to large-sized genomic regions
at a single nucleotide resolution. These technological genomic
advancements are able to provide high-throughput screening and
can detect genetic variations in patients with high accuracy and
reduced cost. Although scientists and policy advisers deal inten-
sively with the interpretation and handling of the onslaught and
ambiguity of genome-wide data, we are rapidly moving toward a
new era of genetic research for BrS, which is full of opportunities
as well as a mountain of challenges.2. Terminology
2.1. Polymorphism vs. mutation
The genome of any person is more than 99% similar to that of
an unrelated individual. This tiny variability allows individuals to
be distinguished by means of genetic testing. When a nucleotideFig. 1. An example of a representative multi-generation pedigree displaying incomplete p
without any cardiac events.change occurs in more than 1% of the general population, it is
called a “polymorphism.” In contrast, a mutation occurs in less
than 0.5% of the population and is deﬁned as a permanent change
in the nucleotide sequence that results in altered amino acids. The
terms “mutation” and “polymorphism” have been used widely but
often lead to confusion because of incorrect assumptions regard-
ing their respective pathogenic and benign effects. In 2015, the
American College of Medical Genetics and Genomics (ACMG)
recommended that both terms be replaced by the term “variant”
with the following modiﬁers: (i) pathogenic, (ii) likely pathogenic,
(iii) uncertain signiﬁcance, (iv) likely benign, or (v) benign [3].2.2. Penetrance and expressivity
In medical genetics, penetrance is the proportion of individuals
with the mutation who exhibit clinical symptoms. For example, in
a family with 10 members, if 4 out of 10 are carriers of a patho-
genic variant in the SCN5A gene but only 2 of the 4 carriers have
type 1 BrS ECG, the penetrance in this family is 50%. The pene-
trance of BrS is lower than that of the congenital long QT syn-
drome. In a study conducted in 2000, Priori et al. estimated that
the overall disease penetrance across 4 small BrS families har-
boring mutations in the SCN5A gene was 16% based on their ECG
analysis (range 12.5–50%) [4]. In contrast, the mean penetrance
across multiple long QT syndrome subtypes in a population-based
study was shown to be 40% (range 25–100%) [5,6] (Fig. 1).
Expressivity is used to describe the variations in a phenotype
among individuals carrying the same pathogenic variants. Differ-
ent degrees of expression in different individuals may be due to
variation in the allelic constitution of the remaining genome or
due to environmental factors. For example, individuals in the same
BrS family who carry the same SCN5A pathogenic variant could
show different electrocardiographic patterns ranging from Bru-
gada type I ECG to conduction disturbance, or even long QT.enetrance (33%) and variable expressivity as some individuals display Brugada ECG
J.-M.J. Juang, M. Horie / Journal of Arrhythmia 32 (2016) 418–4254203. Clear clinical diagnosis of Brugada syndrome before genetic
testing
Many clinical conditions may lead to ST-segment elevation in
the right precordial leads, which mimic the BrS ECG patterns. For
example, exposure to some drugs and ionic imbalance may pro-
duce a Brugada-like ST-segment elevation. Previous reports have
described this as an acquired Brugada syndrome or Brugada
phenocopy. It presents with an ECG pattern identical to type I
(Coved), type 2, or type 3 (Saddleback) Brugada patterns but dif-
fers etiologically from true BrS. Prior to diagnosis of the true or
congenital Brugada syndrome, all of the following conditions
should be ruled out (Table 1).
Acquired BrS usually has an identiﬁable underlying condition
that elicits a BrS ECG pattern. Once the underlying condition is
resolved, the ECG normalizes completely. Provocative testing with
ﬂecainide, ajmaline, pilsicainide, procainamide, or other sodium
channel blockers is an important method to differentiate con-
genital BrS from acquired BrS. The result of these tests should be
negative in patients with acquired BrS. The ﬂowchart for such
testing is shown in Fig. 2.
After clinical conﬁrmation of congenital BrS, genetic testing is
recommended for patients with congenital BrS but is not man-
datory for those with acquired BrS. Thus, it is important to make a
clear BrS diagnosis before conducting genetic tests.Fig. 2. The ﬂowchart for differentiating congenital BrS from acquired BrS before
conducting genetic tests.4. Genetic background of Brugada syndrome
In 1996, the term “Brugada syndrome” was used to describe
what was known as “right bundle branch block, persistent ST
segment elevation, and sudden death syndrome”[7]. In 1998, the
ﬁrst BrS-associated gene, SCN5A, which encodes the alpha-subunit
of the voltage-gated Nav1.5 cardiac sodium channel, was reported
to be associated with the disease [8]. In the past 2 decades, several
BrS-associated genes and modiﬁer genes were reported and most
of these primarily encode sodium, potassium, and calcium chan-
nels or the proteins associated with these channels (Table 2 and
Fig. 3). Despite these genetic studies, only 30–35% of clinically
diagnosed cases can be genetically diagnosed, indicating that 65–
70% of BrS patients remain genetically unresolved.
4.1. Differing ethnic background of Brugada syndrome
As early as 1917 sudden unexpected nocturnal death (SUND) in
young, apparently healthy, adults has been reported in Manila,
Guam, and Hawaii [9,10]. Although the exact prevalence of BrS is
still uncertain, it presents marked geographical differences. It was
estimated to affect 5/10,000 individuals in Western countries and
12/10,000 individuals in Southeast Asia [11,12], especially in
Thailand and the Philippines where Brugada syndrome is con-
sidered to be the leading cause of sudden death in young men.Table 1
Common causes of acquired Brugada syndrome or Brugada phenocopy.
Category Examples
Metabolic factors or electrolytes Hypothermia, adrenal crisis/insufﬁciency, hyper
Neuromuscular Diseases Duchenne's muscular dystrophy, spinal and bulb
Toxin or poison Cannabis, cocaine, ethanol, heroin, ketamine, alu
Mechanical compression Rhabdomyoma of the interventricular septum/me
hemopericardium
Vascular factors RV infarction, pulmonary embolism, Dissecting a
Myocardial and Pericardial Disease Chagasic cardiomyopathy, cardiac amyloidosis, m
ECG modulation Improper application of a high pass ﬁlter (ex. 0.5
Miscellaneous Repaired pentalogy of Fallot, electrocutionAfter pooling all the community-based and hospital-based popu-
lation studies in the world, type 1 ECG was found to appear more
frequently in Asia (0–0.36%) and Europe (0–0.25%) than in the
United States (0.03%). Type 2 and type 3 ECG is more prevalent in
Asia (0.12–2.23%) than in Europe (0–0.6%) or the United States
(0.02%) [13]. Data from subjects of African origin are highly scarce.
Conﬁning the analyses to community-based studies, which may be
more representative of the general population, Asia still shows the
highest prevalence of type 1 ECG globally (0–0.67%). There is a
greater burden of sudden cardiac death due to BrS in Asian regions
than that in Europe or America.
In 1998, Chen et al. reported that BrS has a genetic abnormality
linked to mutations in SCN5A, which are present in 20–25% of BrS
cases in Caucasian populations [8,14]. In previous Japanese studies,
the mutation rate of SCN5A was around 11–14% (personal com-
munications) whereas in the Han Chinese population, o10% BrS
patients SCN5Ain Taiwan had SCN5A mutations [15]. This implied
that the distribution of disease-causing genes among BrS patients
in the Asian population might differ from that in the Caucasian
population. Furthermore, certain SCN5A promoter polymorphisms
in a haplotype variant with a relatively high prevalence in Asians,
were reported to not only reduced transcriptional activity in vitro,
but also modulate variability in cardiac conduction as assessed by
PR and QRS durations [16]. These observations implied the exis-
tence of variations in the genetic architecture of Asian BrS and
Caucasian, which requires further research.
4.2. Sodium channel
SCN5A, the most common BrS-associated gene, was identiﬁed
in approximately 20-25% of BrS patients. Until 2010, almost 300
SCN5A mutations have been reported in BrS, which includeor hypokalemia, hypercalcemia
ar muscular atrophy (SBMA), Friedreich ataxia, myotonic dystrophy [68]
minium phosphide fatal poisoning
diastinal lipoma/mass lesions, pectus excavatum, post-esophageal reconstruction,
ortic aneurysm
yocarditis, pericarditis, Arrhythmogenic right ventricular dysplasia
-Hz ﬁlter)
Table 2
Identiﬁed genes and modiﬁer genes linked to Brugada syndrome.
BrS subtype Ion channel BrS-associated
Gene
Locus Protein Functional Effect % of Disease Reference
BrS1 Sodium channel SCN5A 3p21 Nav1.5 LOF 20–25 (Caucasian);
10-15 (Asian)
[8,17]
BrS5 SCN1B 19q13.1 Navβ1 LOF 1–2 [25,38]
BrS17 SCN2B 11q23 Navβ2 LOF Rare [26]
BrS7 SCN3B 11q23.2 Navβ3 LOF Rare [27]
BrS18 SCN10A 3p22.2 Nav1.8 LOF 2.5–16 [28–31,46]
BrS11 Sodium channel-
associated
RANGRF 17p13.1 MOG1 LOF Rare [32]
BrS2 GPD1-L 3p24 G3PD1L LOF Rare [33,38]
BrS15 SLMAP 3p21.2-p14.3 SLMAP LOF Rare [34]
BrS20 PKP2 12p11.21 plakophilin-2 plakophilin-2 cause
sodium current deﬁcit
2.5 [35]
BrS16 TRPM4 19q13.33 NSCCa LOF 8 [36]
BrS3 Calcium channel CACNA1C 12p13.3 Cav1.2 LOF 6–7 [37,38]
BrS4 CACNB2b 10p12.33 Cavβ2 LOF 4–5 [37,38]
BrS10 CACNA2D1 7q21-22 Cavα2δ1 LOF Rare [39]
BrS21 Potassium channel ABCC9 12p12.1 SUR2A (sulfonylurea receptor
subunit 2 A), IK-ATP
GOF 4–5 [44]
BrS13 KCND3 1p13.2 Kv4.3, Ito GOF Rare [40]
BrS6 KCNE3 11q13-14 MiRP2, Ito/Iks GOF o1 [38,41]
BrS9 KCNJ8 12p12.1 Kir6.1, IK-ATP GOF Rare [43,69]
BrS8 KCNH2 7q35 Kv11.1, Ikr GOF 1–2 [45]
BrS-modiﬁer
Gene
BrS19 Sodium channel HEY2 6q22 Nav1.5 LOF ? [46]
BrS14 Potassium channel HCN4 15q24.1 If LOF Rare [47,70]
BrS12 KCNE5 Xq22.3 MiRP4, Kv4.3, Ito GOF Rare [42]
Fig. 3. Schematic representation of a cardiomyocyte exhibiting the proteins involved in Brugada syndrome pathogenesis.
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deletions, and splice site mutations [17]. The number of SCN5A
mutations is still increasing. SCN5A is responsible for the fast
upstroke in phase 0 of the cardiac action potential, and pathogenic
variations result in sodium channel dysfunction, which leads to
slowing of conduction in the heart. Functional studies of these
mutations revealed loss of function in the sodium channels that
was affected through different mechanisms including decreased
expression of the sodium channel protein (Nav1.5) in the sarco-
lemma [18], expression of non-functional channels [19], or altered
gating properties (delayed activation, earlier inactivation, faster
inactivation, enhanced slow inactivation, and delayed recovery
from inactivation) [20–24].
Besides SCN5A genes, many BrS-related genes play a role in
regulating sodium channel function. Several pathogenic variationsin three genes (SCN1B, SCN2B, and SCN3B) encoding the β subunits
of the Nav1.5 sodium channel, have been discovered to modify the
channel function. SCN1B encodes the β1- and β1b- subunits, which
are auxiliary function-modifying subunits of the cardiac Naþ
channel, and decreases the INa current by affecting Naþ channel
trafﬁcking [25]. SCN2B encodes the β2-subunit of the Naþ cardiac
channel. The D211G mutation in SCN2B decreases Nav1.5 expres-
sion on CHO cells [26]. Mutations in SCN3B, which encodes the β3-
subunit of the Naþ cardiac channel, and leads to a loss of function
in the Naþ cardiac channel, is also reported to cause BrS [27].
SCN10A, encodes the neuronal sodium channel Nav1.8, and mod-
ulates SCN5A expression and the electrical function of the heart; it
is reported that mutations in SCN10A account for 16% of patients
with the typical BrS identiﬁed in a cohort of 150 BrS affected
Caucasian individuals [28]. However, three more studies have
J.-M.J. Juang, M. Horie / Journal of Arrhythmia 32 (2016) 418–425422reported a lower percentage of SCN10A mutation in the SCN5A
mutation negative BrS in the Caucasian (3.8%) and Japanese BrS
patients (2.5%) [29–31]. Determining the true prevalence of
SCN10A mutations in patients with BrS requires more data from
different ethnicities.
4.3. Sodium channel-associated
RAN guanine nucleotide release factor (RANGRF) gene, encod-
ing MOG1, was reported to impair the trafﬁcking of Nav1.5 to the
membrane, leading to INa reduction [32]. Mutations in the
glycerol-3-phosphate dehydrogenase 1-like gene (GPD1L) may also
affect the trafﬁcking of cardiac Naþ channels to the cell surface
and cause 50% reduction in the inward Naþ current [33]. The
gene for sarcolemmal membrane-associated protein (SLMAP) that
is found in T-tubules and in the sarcoplasmic reticulum, which has
an unknown function, causes BrS by modulating the intracellular
trafﬁcking of the Nav1.5 channel [34]. The gene for Plakophilin-2
(PKP2) was the primary gene responsible for arrhythmogenic right
ventricular cardiomyopathy (ARVC). Recently, a correlation was
identiﬁed between the loss of PKP2 expression PKP2 and reduced
INa in BrS patients [35]. The transient receptor potential melastatin
protein number 4 (TRPM4) is a calcium-activated nonselective
cation channel, that is a member of a large family of transient
receptor potential genes; of 248 BrS cases without SCN5A muta-
tions, 8% SCN5Acarry mutations in TRPM4. Because of its effect on
the resting membrane potential, both reduction and increase in
TRPM4 channel function, may reduce the availability of Naþ
channels and thus lead to BrS [36].
4.4. Calcium channel
BrS-susceptibility genes were also found among calcium
channels (CACNA1C, CACNB2b, and CACNA2D1). Mutations in CAC-
NA1C and CACNB2b are associated with 11.5% of BrS cases, wherein
patients generally present with shorter-than normal QT intervals
[17]. Putative mutations in the genes encoding the calcium chan-
nel, the voltage-dependent, L-type, α1c subunit (CACNA1C), and
the β2b subunits (CACNB2b) of the L-type cardiac Ca2þ channel
caused a decrease in ICa current, resulting in a combined BrS/short
QT syndrome [37,38]. CACNA2D1, encoding the calcium channel,
voltage-dependent, L-type, α2/δ subunit 1, regulates the current
density and activation/inactivation kinetics of the Ca2þ channel
and is associated with BrS [39].
4.5. Potassium channel
Apart from sodium and calcium channels, putative gain of
function mutations in genes encoding channels that conduct
outward potassium currents (KCND3, KCNE3, KCNE5KCNE5, and
KCNJ8) have also been reported in a few BrS cases. Mutations in
KCND3 genes, encoding a Kv4.3 potassium voltage-gated channel,
Shal-related subfamily, member 3, lead to an increase of the Ito
current in the right ventricle, and have been linked to BrS [40].
KCNE3 (encoding MiRP2) is a protein that decreases the potassium
(Kþ) transient outward current (Ito) current by interacting with
the channel Kv4.3, and results in increased Ito magnitude and
density in the human heart [38,41]. KCNE5 (KCNE1L) is located on
the X chromosome and encodes an auxiliary β-subunit for K
channels (potassium voltage-gated channel, Isk-related family,
member 5). Mutations in KCNE5 modiﬁed potassium channels that
lead to an increase in the Ito current have been linked to BrS [42].
Potassium inwardly rectifying channel, subfamily J, member 8
(KCNJ8) gene encodes Kir6.1 [43]. The gene for ATP-binding cas-
sette, subfamily C member 9 (ABCC9) encodes the sulfonylurea
receptor subunit 2 A (SUR2A) [44]. Functional KATP channels havean octameric subunit structure with four pore-forming subunits
(Kir6.1) and four sulfonylurea receptors (SUR2A). Gain-of-function
mutations in KATP channels induced by pathogenic variants in
KCNJ8 or ABCC9, accompanied with loss-of-function pathogenic
variants in SCN5A may result in a severe arrhythmic phenotype of
BrS [43]. Four KCNH2 mutations, T152I, R164C, W927G, and
R1135H were identiﬁed in 236 Japanese consecutive probands
with BrS or Brugada-like ECG. Three of these mutation carriers
showed QTc intervals shorter than 360 milliseconds and one
experienced VF. Patch-clamp analyses showed that all KCNH2
mutations exerted gain-of-function effects on IKr channels in CHO
cells [45].
4.6. Potassium channel-associated
In a transgenic mouse study, HEY2, which encodes the tran-
scriptional repressor hairy/enhancer-of-split related with YRPW
motif protein, was found to play a role in the regulation of SCN5A
expression and conduction velocity in the heart, suggesting that
BrS may originate from altered transcriptional programming dur-
ing cardiac development. One SNP, rs9388451 near the HEY2 gene
was signiﬁcantly associated with BrS through a genome-wide
association study in 312 individuals with BrS [46]. HCN4 encodes
the hyperpolarization activated cyclic nucleotide-gated potassium
channel 4, which is a voltage-gated ion channel mediating the
pacemaker (If) current in the heart. It has been reported in a few
BrS patients, but its causative role is still not clear [47,48].
Until now, GPD1L is the only gene identiﬁed by a classical
genetic linkage study, whereas all other genes were identiﬁed only
in a single patient, in a few unrelated patients, or in small families
through candidate gene analysis [17]. This is an important lim-
itation that deserves further study before genes are implicated in
the pathogenesis of BrS or any other disease entity [49].
4.7. Inherited model of BrS
The inheritance of BrS was believed to present an autosomal
dominant mode of transmission with incomplete penetrance [50].
The penetrance of BrS is age- and sex-dependent and most lethal
events occur in men after the fourth decade of life [51,52]. In a
long-term follow-up study, age-related depolarization abnormal-
ities (e.g. slowing of conduction) in the heart modulate the clinical
ECG phenotype [53], especially in patients with SCN5A-positive
mutations. Gender is also a modiﬁer of both ECG phenotype and
the risk of SCD in BrS [54]. The relative risk for cardiac events in
men is 3.34 times that in women. These sex-speciﬁc differences
may be linked to the differential effect of sex hormones on cardiac
ion channel current densities and functional cardiac repolarization
reserves [6].
In the past decades, more observations suggest that BrS has a
heterogeneous genetic basis and is a disease with a more complex
inheritance. Overall, o40% of BrS cases are familial, whereas other
cases are sporadic. Despite its symptomatic or asymptomatic sta-
tus, a positive family history of sudden cardiac death at a young
age (o45 years) in BrS patients was quite low (10–30%). In
addition, low disease penetrance was observed based on ECG
analysis in family members carrying SCN5A mutations (12.5–50%,
average 16%) [4]. In a study with large families that had at least
5 family members carrying SCN5A mutations, 8 SCN5A mutation-
negative BrS individuals were identiﬁed in 5 families (3 belonging
to 3 different families) [55]. Furthermore, familial linkage analyses
have largely been unsuccessful in uncovering new disease-causing
genes because most of the BrS families are rather small for pow-
erful linkage analysis, low penetrance, and variable expressivity of
diseases. In a GWAS study, Bezzina et al. identiﬁed three common
genetic variants that contributed to BrS susceptibility [46]. Disease
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risk alleles, when these loci were considered in aggregate [16]. The
above observations provide evidence that the genetic architecture
of BrS could be more complicated than we have understood until
date and it is more like an oligogenic disease.4.8. Overlapping syndromes and genetic heterogeneity of BrS
After two decades, the SCN5A gene has become the most
common BrS-causing gene [56]. However, several reports have
demonstrated increasing clinical and biophysical overlap among
various types of SCN5A mutations, referred to as an “overlap
syndrome” of cardiac sodium channel disease [57]. A single
mutation in SCN5A can cause several phenotypes in the same
family or in a single patient, such as BrS, long QT syndrome type 3
(LQTS3), sick sinus syndrome, and cardiac conduction diseases
[58]. A pathogenic variant in the SCN5A gene has been identiﬁed in
patients affected by the early repolarization syndrome (ERS) [59].
The presence of progressive cardiac conduction disease (PCCD) in
BrS families is frequent and has been described as a different
expression of the BrS genetic phenotype. Several pathogenic var-
iations in the SCN5A gene are associated with both PCCD and BrS
[60]. One gene could result in multiple phenotypes, even in one
family. The BrS and sick sinus syndrome (SSS) were both identiﬁed
within a single family to be caused by a SCN5A mutation causing
loss-of-function in INa [61]. One particular mutation may cause a
mixed clinical phenotype in one carrier, and to a single arrhythmia
syndrome in another. The reasons for this remain largely elusive.
Clinical and genetic diagnoses of SCN5A-related overlap syn-
dromes are often complicated further by reduced penetrance and
variable disease expressivity, even within a single family. Large
cohorts of patients carrying the same overlap syndrome with an
SCN5A mutation are needed to gain more insight into the different
factors that determine disease severity, expressivity, and outcome.
The genetic heterogeneity of BrS showed overlapping genetic
features with other inherited arrhythmia diseases (ERS, PCCD, SSS,
short QT syndrome, LQTS3, and arrhythmogenic right ventricular
cardiomyopathy). The genes associated with both BrS and other
inherited arrhythmia diseases are shown in Fig. 4.Fig. 4. Genes associated with Brugada syndrome (BrS) and other inherited
arrhythmia diseases.5. The role of genetic testing in the clinical practice for Bru-
gada syndrome
BrS is partly a cardiac disorder, with an autosomal dominant
inheritable model showing incomplete penetrance. The current
expert consensus statement recommends mutation-speciﬁc
genetic testing for family members and appropriate relatives fol-
lowing identiﬁcation of the BrS-causative mutation in an index
patient (Class I recommendation) [62]. The primary role of genetic
testing in BrS is to conﬁrm the disorder in the index patient, and
cascade testing in relatives to distinguish those who need clinical
follow-up (for development of conduction disease or syncopal
episodes) and preventive measures (e.g., avoiding speciﬁc drugs,
prompt management of fever) from those who are both clinically
and genetically unaffected [56,63].5.1. Genetic testing for diagnostic implications
BrS is diagnosed clinically (type 1 Brugada ECG pattern) at this
point. The result of genetic testing is not considered one of the
criteria for BrS diagnosis. Genetic testing is not recommended in
the absence of a diagnostic ECG. Nevertheless, comprehensive or
SCN5A targeted genetic testing can be useful for any patient in
whom a cardiologist has established a clinical index of suspicion
for BrS based on clinical examination (patient's clinical history,
family history, and ECG phenotype) [56]. In addition, mutation-
speciﬁc genetic testing in family members of successfully geno-
typed probands may play a decisive role in determining who
should take precautions in certain conditions and who should be
followed-up. Both clinically diagnosed BrS patients and asympto-
matic SCN5A mutation-positive subjects are advised to treat fever
with antipyretic drugs immediately, and to avoid intake of exces-
sive alcohol and drugs that decrease sodium channel availability
and functionality [56].5.2. Genetic testing for prognosis
The data linking genetic information to clinical prognosis are
being accumulated but are still limited at this moment. In a pre-
vious meta-analysis and results from the FINGER Brugada Syn-
drome registry, the status of SCN5A mutations does not seem to be
an independent risk factor for future cardiac events (syncope or
SCD) [54,64]. However, in a subset analysis for mutation types,
patients carrying an SCN5A mutation that causes a prematurely
truncated protein (stop codon or frameshift), were more likely to
present with syncope and develop prolonged PR and QRS intervals
(increased conduction delay at different levels in the heart) com-
pared to patients harboring missense SCN5A mutations [65]. In
2010, Nishii et al. reported that the shock-free survival rate was
signiﬁcantly lower in BrS patients with SCN5A mutations than that
in those without SCN5Amutations in the Japanese population [66].
In the Han Chinese population, we observed that SCN5A mutations
may not be a predictor of recurrent arrhythmic events in symp-
tomatic BrS patients, but may predict the timing of the onset of the
ﬁrst cardiac event in a study from Taiwan (unpublished data).5.3. Genetic testing for treatment
Compared to the long QT syndrome, the genetic evidence of BrS
for adjusting treatment is scarce at this point. The result of genetic
testing does not have an impact on the decision for choosing
medications or for ICD implantation.
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counseling
Although the current expert consensus statement recommends
that comprehensive or BrS1 (SCN5A) targeted BrS genetic testing
can be useful for genetic testing [63], not all the published SCN5A
mutations in BrS have been subjected to functional analysis, and
2–5% background rate of rare variants was reported in healthy
subjects [17]. Before the exome data from the NHLI GO Exome
Sequencing Project (ESP) was published in 2012, the distribution
of genetic variations in BrS-associated genes from the large gen-
eral population was still elusive. Upon reviewing the published
variants associated with BrS, ESP harbored 22 of 303 (7%) variants
in SCN5A [67]. Many variants were originally thought to be disease
causing based on their absence in modestly sized healthy controls,
but they could possibly be rare or low frequency benign variants.
In addition, SCN5A mutations in BrS are also known to have
incomplete penetrance and variable expressivity. As a result,
careful interpretation of identiﬁed variants is extremely important
for BrS patients or family members, especially for single probands
or for single small families. Genetic counseling that outlines the
possible explanations of genetic results and multidisciplinary
clinics are essential to unravel the complicated questions from
patients and family members.7. Perspectives
Genetics is one of the links between basic science and clinical
medicine. Advances in genetics could probably improve the future
diagnosis, identiﬁcation of possibly affected individuals, risk stra-
tiﬁcation, treatment, and prevention of BrS. Research in genetics is
emerging at this point with many hopes and challenges. BrS has
been recognized for more than two decades and many studies on
BrS have disclosed part of its genetic underpinning, pathophysio-
logical mechanisms, clinical characteristics, and electro-
physiological ﬁndings. However, many questions remain unre-
solved with regard to the exact mechanisms, the complete genetic
architecture, the role of polymorphisms and gene modiﬁers, and
the environmental factors (e.g., hormones, fever) involved. Using
new molecular biotechnological techniques like next-generation
sequencing (exome or whole genome sequencing), we expect that
more BrS-associated genes would be detected in the near future.
With more genetic data, personalized treatment may be available
in the future although we are just at the beginning of the mole-
cular genetics era. Finally, the ﬁeld of genetics is moving extremely
faster than expected. Validating the present data periodically with
the most up-to-date information regarding BrS is therefore
necessary.Funding
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